Price for REN (US) takeover by Gambro has risen:
This article was originally published in Clinica
Swedish Gambro's US subsidiary, Cobe Laboratories, and REN (US) have signed a definitive merger agreement at a higher price than announced in July. Instead of $18 a share, REN shareholders will receive $20 per share in cash (see Clinica No 664, p 16). Even before the tender offer, Cobe owned 53% of REN. When the merger is complete, REN will become a wholly-owned subsidiary of Cobe.